SEC Form 4 · accession 0001179110-16-032850
IMMUNOGEN INC · IMGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Alan Goldberg
Director
Period of report
Dec 9, 2016
Accepted (ET)
Dec 13, 2016 · 10:55 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000855654
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Share UnitF1,F3,F2 | $0.00 | Dec 9, 2016 | A | 1,500 | A | Mar 1, 2017 | — | Common Stock | 1,500 | 27,657 | D |
| Stock option (right to buy)F4 | $1.84 | Dec 9, 2016 | A | 5,000 | A | Mar 1, 2017 | Dec 9, 2026 | Common Stock | 5,000 | 5,000 | D |
Explanation of responses
- F1The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.
- F2The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.
- F3The deferred share units vest one-half on March 1, 2017 and one-half on June 1, 2017, contingent upon the individual remaining a director as of each vesting date.
- F4Exercisable as to 2,500 shares commencing on February 1, 2016, 2,500 shares commencing on May 1, 2016, 2,500 shares commencing on August 1, 2016 and 2,500 shares commencing on November 1, 2016, contingent upon the individual remaining a director as of each vesting date.